Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | NPY1R | P25929 | 1/20 | 0.51 |
| ▸ | NPY2R | P49146 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | PDE3B | Q13370 | 9/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 8/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | PDE1A | P54750 | 1/20 | 0.42 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.42 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 4/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21241239 | 0.90 | KCNH2 (0.52) | MAPTLMNANPY1RNPY2RKCNH2 | |
| SCHEMBL21241228 | 0.84 | KCNH2 (0.56) | MAPTLMNANPY1RNPY2RKCNH2 | |
| SCHEMBL21241015 | 0.82 | PDE3B (0.53) | MAPTLMNANPY1RNPY2RKCNH2 | |
| SCHEMBL21241022 | 0.81 | KCNH2 (0.52) | MAPTLMNANPY1RNPY2RKCNH2 | |
| SCHEMBL21241242 | 0.81 | KCNH2 (0.52) | MAPTLMNANPY1RNPY2RKCNH2 | |
| SCHEMBL21241241 | 0.78 | KCNH2 (0.58) | MAPTLMNANPY1RNPY2RKCNH2 | |
| SCHEMBL21241427 | 0.78 | PDE3B (0.64) | MAPTLMNAPDE3BSMN1; SMN2PDE3A | |
| SCHEMBL21241021 | 0.78 | KCNH2 (0.52) | MAPTLMNANPY1RNPY2RKCNH2 | |
| SCHEMBL10990539 | 0.77 | PDE3B (0.53) | MAPTLMNANPY1RNPY2RKCNH2 | |
| SCHEMBL10995551 | 0.77 | MAPT (0.52) | MAPTLMNANPY1RNPY2RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11512056-B2 | Guanidyl-containing P2Y12 receptor antagonist and preparation method and application thereof | ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD (CN) | 2022-11-29 | — | — | US | claimed |
| CN-110117257-B | P2Y12 receptor antagonist containing guanidyl as well as preparation method and application thereof | 安徽省新星药物开发有限责任公司 | 2022-12-06 | — | — | CN | disclosed |
| US-11512056-B2 | Guanidyl-containing P2Y12 receptor antagonist and preparation method and application thereof | ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD (CN) | 2022-11-29 | — | — | US | disclosed |
| US-20210078954-A1 | GUANIDYL-CONTAINING P2Y12 RECEPTOR ANTAGONIST AND PREPARATION METHOD AND APPLICATION THEREOF | ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD (CN) | 2021-03-18 | — | — | US | disclosed |
| US-20210078954-A1 | GUANIDYL-CONTAINING P2Y12 RECEPTOR ANTAGONIST AND PREPARATION METHOD AND APPLICATION THEREOF | ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD (CN) | 2021-03-18 | — | — | US | disclosed |
| EP-3766872-A1 | P2Y12 RECEPTOR ANTAGONIST CONTAINING GUANIDYL, AND PREPARATION METHOD AND USE THEREOF | Anhui New Star Pharmaceutical Development Co., Ltd (CN) | 2021-01-20 | — | — | EP | disclosed |
| WO-2019149259-A1 | P2Y12 RECEPTOR ANTAGONIST CONTAINING GUANIDYL, AND PREPARATION METHOD AND USE THEREOF | 安徽省新星药物开发有限责任公司 | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078954-A1 | GUANIDYL-CONTAINING P2Y12 RECEPTOR ANTAGONIST AND PREPARATION METHOD AND APPLICATION THEREOF | P2RY12, P2RY13, P2RY11 | MAPT 3866/4885LMNA 773/4885NPY1R 262/4885 |
| US-11512056-B2 | Guanidyl-containing P2Y12 receptor antagonist and preparation method and application thereof | P2RY12, P2RY13, P2RY11 | MAPT 3866/4885LMNA 773/4885NPY1R 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.